DNA Data Shared in Ways Patients May Find Surprising
August 13, 2019
(The Wall Street Journal) – Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to patient information because of the data’s potential to help unlock disease insights and discover new drugs. They are striking deals to sequence patients’ genetic code, including with hospital systems like Geisinger in Pennsylvania, Mount Sinai Health System in New York and Mayo Clinic in Minnesota.